Item 2.01
Completion of Acquisition or Disposition of Assets.
On December 12, 2018, the Company completed the previously announced merger pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018, as amended on October 1, 2018 (the Merger Agreement), by and among Keryx Biopharmaceuticals, Inc. (Keryx), Akebia, and Alpha Therapeutics Merger Sub, Inc., a wholly owned subsidiary of Akebia (Merger Sub). Pursuant to the Merger Agreement, Merger Sub merged with and into Keryx, with Keryx becoming a wholly owned subsidiary of Akebia (the Merger).
At the consummation of the Merger, each issued and outstanding share of common stock of Keryx, $0.001 par value per share, was converted into 0.37433 of a share of Common Stock, and cash in lieu of fractional shares.
The issuance of Common Stock in connection with the Merger was registered under the Securities Act of 1933, as amended, pursuant to Akebias registration statement on Form S-4 (File No. 333-227622) filed with the United States Securities and Exchange
No. 333-227622)
